GlassScriptPhysician profile
Mark Oberdoerster
NPI 1932197423
$1,464.74
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,081 · 2020: $259 · 2022: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $330.66 | 2019-2020 | |
| Novo Nordisk INC | $180.98 | 2019-2020 | |
| Pfizer INC. | $138.70 | 2019-2020 | |
| Genzyme Corporation | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $118.78 | 2019-2020 | |
| Amgen INC. | $103.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $52.75 | 2019-2020 | |
| Lilly USA, LLC | $49.85 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $44.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.58 | 2019 | |
| Glaxosmithkline, LLC. | $29.95 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.69 | 2019-2020 | |
| Sanofi Pasteur INC. | $26.96 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.95 | 2019 | |
| Horizon Therapeutics Plc | $19.42 | 2019 | |
| Amarin Pharma, INC. | $12.87 | 2019 | |
| Circassia INC. | $12.16 | 2019 | |
| Mannkind Corporation | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Oberdoerster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.